Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
New drugs offer options for patients with drug-resistant tuberculosis (DR-TB). We describe four individuals with DR-TB in KwaZulu-Natal, South Africa, with prior exposure to clofazimine who would benefit from access to delamanid (DLM). Without DLM, individual options are limited, and there is a risk of resistance amplification and both community and nosocomial spread of DR-TB.
Department of Tuberculosis, King Dinuzulu Hospital, Durban, South Africa.
I
I
Master
Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
J
J
Furin
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D054908:Extensively Drug-Resistant Tuberculosis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D008297:Male; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010080:Oxazoles / Q000627:therapeutic use*; D013019:South Africa; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D055815:Young Adult
D000995:Antitubercular Agents; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles